In January, Endocrine News reported on the possible upcoming availability of teprotumumab as a promising treatment for of thyroid eye disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Up to 50% of patients with Graves’ disease...
